Table 2 Open issues for bisphosphonate adjuvant treatment in early breast cancer trials
From: Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
Patient-related issues | Biological issues |
|---|---|
Histological type (ductal, lobular, etc.) | Preclinical models: how closely do animal models of a low-estrogen environment mimic the postmenopausal status in women with breast cancer? |
Molecular subtype (luminal, triple negative breast cancers, etc.) | Type of bisphosphonate (amino vs non-amino): superiority of one bisphosphonate in selective setting? |
Clinical and pathological stage of disease | Interaction with hormone therapy and chemotherapy: synergy or not? |
Estrogen and progesterone levels | Duration of bisphosphonate therapy: how long? |
Menopausal status (different menopausal definition in trials) | Â |
Comorbidities | Â |
Personal factors | Â |